 Heidelberg, Germany, January 15, 2021 Affimed N.V. Affimed or the Company Nasdaq: AFMD, a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the closing of its previously announced public offering of 16,666,667 common shares, at the public offering price of 6.00 per share, and the exercise in full by the underwriters of their option to purchase an additional 2,500,000 common shares. The exercise of the option to purchase over-allotment shares brought the total number of common shares sold by Affimed to 19,166,667 common shares and increased the gross proceeds raised in the offering, before deducting underwriting discounts and commissions and estimated expenses of the offering payable by Affimed, to 115 million. 